Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults
- 1 June 2011
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 31 (6) , 407-415
Abstract
Background and Objective: Sporadic cases of renal toxicity have been reported in HIV-infected children treated with tenofovir disoproxil fumarate (TDF). We assessed the long-term renal safety of TDF in a cohort of vertically HIV-infected children, adolescents and young adults. Methods: We evaluated 26 HIV-infected children, adolescents and young adults, aged 4.9–17.4 years at baseline, every 6 months for 60 consecutive months. At the baseline visit, they had an undetectable viral load and a good immune reconstitution and were being treated with lamivudine, stavudine and a protease inhibitor (PI). At the same visit, stavudine was replaced with TDF and the PI with efavirenz. Serum creatinine, estimated glomerular filtration rate (GFR), urine protein to creatinine ratio, serum phosphate, ratio of the maximum rate of tubular phosphate reabsorption to the GFR (TmPO4/GFR), urine glucose, and urine α1-microglobulin to creatinine ratio were used as markers of renal function. The outcome-time relationships were studied using generalized estimating equations (GEEs). In addition to time (continuous, ten equally spaced intervals), sex, age at baseline and CD4+ T-cell count were used as covariates. Results: A moderate reduction in GFR was observed only once in an underweight female patient. There was no occurrence of proteinuria, hypophosphataemia or glycosuria. Moreover, TmPO4/GFR was stable and the urine α1-microglobulin to creatinine ratio was always within normal limits. Conclusion: TDF had an excellent renal safety profile in HIV-infected children, adolescents and young adults regularly followed up for 60 months.Keywords
This publication has 38 references indexed in Scilit:
- Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control studyAIDS, 2010
- Incidence of Persistent Renal Dysfunction in Human Immunodeficiency Virus-Infected ChildrenThe Pediatric Infectious Disease Journal, 2009
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Long-Term Evaluation of Glucose Homeostasis in a Cohort of HAART-Treated HIV-Infected ChildrenClinical Drug Investigation, 2009
- INCREASED β-2 MICROGLOBULINURIA IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED CHILDREN AND ADOLESCENTS TREATED WITH TENOFOVIRThe Pediatric Infectious Disease Journal, 2007
- Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavirPediatric Nephrology, 2006
- Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV InfectionPediatrics, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus MacaquesAntimicrobial Agents and Chemotherapy, 2004
- Italian cross-sectional growth charts for height, weight and BMI (6–20 y)European Journal of Clinical Nutrition, 2002